Biochemia Medica:与常规和诊断性葡萄糖检测相关的分析前问题

2020-02-17 MedSci MedSci原创

糖尿病是世界上最常见的疾病之一。本研究的目的这项研究的目的是找出西班牙实验室在何种分析前条件下进行常规和诊断性葡萄糖测试;以及用于DM诊断的标准。

糖尿病是世界上最常见的疾病之一。本研究的目的这项研究的目的是找出西班牙实验室在何种分析前条件下进行常规和诊断性葡萄糖测试;以及用于DM诊断的标准。

20184月至7月期间,西班牙实验医学协会(SEQC-ML)的质量委员会进行了一项在线调查。该调查可以通过SEQC-ML网站的主页访问问卷。使用IBM SPSS©Statistics (version 20.0)程序进行数据分析。

本研究共获得有效问卷96份。大多数实验室都是公立正的,为医院和初级保健患者提供服务,工作负担为高和中等,并且以混合的常规-紧急葡萄糖检测为主。血清管最常用于常规葡萄糖分析(92%)和糖尿病诊断(54%); 其次是锂肝素血浆管(62%),主要用于紧急葡萄糖测试; 即时医疗点测试设备的使用率为37%; 装有糖酵解抑制剂(主要是氟化钠)的血浆管和血浆管的含量增加了19%。 实验室使用全球公认的成人DM诊断的临界值和标准以及葡萄糖受损的耐受性,但在空腹血糖和妊娠糖尿病标准方面存在差异。

研究结果表明,在西班牙,常规分析和DM诊断葡萄糖测试的分析前处理无法排除糖酵解对结果的重要非量化影响。因此次导致的可能的不良后果包括诊断延迟和可能的治疗不足。

原始出处:

Isabel García-del-PinoJosep M. BauçaPreanalytical issues related to routine and diagnostic glucose tests: Results from a survey in Spain

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2026280, encodeId=f3a820262809b, content=<a href='/topic/show?id=6cbc915966c' target=_blank style='color:#2F92EE;'>#诊断性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91596, encryptionId=6cbc915966c, topicName=诊断性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83a4244, createdName=swallow, createdTime=Mon Sep 14 00:33:00 CST 2020, time=2020-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859021, encodeId=cfa818590215b, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Jul 02 23:33:00 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918982, encodeId=4b2e191898233, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Nov 05 01:33:00 CST 2020, time=2020-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610263, encodeId=b386161026345, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Feb 19 03:33:00 CST 2020, time=2020-02-19, status=1, ipAttribution=)]
    2020-09-14 swallow
  2. [GetPortalCommentsPageByObjectIdResponse(id=2026280, encodeId=f3a820262809b, content=<a href='/topic/show?id=6cbc915966c' target=_blank style='color:#2F92EE;'>#诊断性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91596, encryptionId=6cbc915966c, topicName=诊断性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83a4244, createdName=swallow, createdTime=Mon Sep 14 00:33:00 CST 2020, time=2020-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859021, encodeId=cfa818590215b, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Jul 02 23:33:00 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918982, encodeId=4b2e191898233, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Nov 05 01:33:00 CST 2020, time=2020-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610263, encodeId=b386161026345, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Feb 19 03:33:00 CST 2020, time=2020-02-19, status=1, ipAttribution=)]
    2020-07-02 jeanqiuqiu
  3. [GetPortalCommentsPageByObjectIdResponse(id=2026280, encodeId=f3a820262809b, content=<a href='/topic/show?id=6cbc915966c' target=_blank style='color:#2F92EE;'>#诊断性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91596, encryptionId=6cbc915966c, topicName=诊断性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83a4244, createdName=swallow, createdTime=Mon Sep 14 00:33:00 CST 2020, time=2020-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859021, encodeId=cfa818590215b, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Jul 02 23:33:00 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918982, encodeId=4b2e191898233, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Nov 05 01:33:00 CST 2020, time=2020-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610263, encodeId=b386161026345, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Feb 19 03:33:00 CST 2020, time=2020-02-19, status=1, ipAttribution=)]
    2020-11-05 sunylz
  4. [GetPortalCommentsPageByObjectIdResponse(id=2026280, encodeId=f3a820262809b, content=<a href='/topic/show?id=6cbc915966c' target=_blank style='color:#2F92EE;'>#诊断性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91596, encryptionId=6cbc915966c, topicName=诊断性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=83a4244, createdName=swallow, createdTime=Mon Sep 14 00:33:00 CST 2020, time=2020-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859021, encodeId=cfa818590215b, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Jul 02 23:33:00 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918982, encodeId=4b2e191898233, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Nov 05 01:33:00 CST 2020, time=2020-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610263, encodeId=b386161026345, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Feb 19 03:33:00 CST 2020, time=2020-02-19, status=1, ipAttribution=)]